Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- REVG +9.9%
Other news:
- RCKT +22.4% (reaches FDA alignment on Phase 2 Trial Design for RP-A501; also prices offering of 7812500 shares of its common stock at $16.00 per share and pre-funded warrants to purchase 3126955 shares of common stock at$15.99 per pre-funded warrant)
- SGML +16.5% (is evaluating potential strategic alternatives)
- MYNZ +13.4% (ColoFuture Study update)
- OCUL +4.4% (submitted a request for a Special Protocol Assessment for the first of the Company's two planned OTX-TKI pivotal trials)
- MRNA +4.1% (expands the field of MRNA medicine with positive clinical results across cancer rare disease and infectious disease)
- SLI +3.2% (acquires large parcel of land for South West Arkansas Project)
- RKLB +2.9% (RKLB signs contract with LDOS to launch four HASTE missions)
- CRNX +2.3% (upsizes and prices offering of 11441648 shares of its common stock at $30.59 per share)
- MOR +2.1% (receives FDA Fast Track designation for tulmimetostat in endometrial cancer)
- RCKY +2% (CFO resigns)
- CECO +1.4% (acquires Kemco Systems; raises FY23 revs outlook)
- JACK +1.2% (names new Del Taco Brand President)
- HRT +1.1% (authorizes additional $25 mln share repurchase program)
Analyst comments:
- SEE +1.1% (upgraded to Outperform from Neutral at Credit Suisse)